# AbelZeta Inc.: Phase 1 study in Systemic Sclerosis (SSc), Systemic Sclerosis (12 participants)

**Score:** 50/100

| Field | Value |
|---|---|
| Sponsor | AbelZeta Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Systemic Sclerosis (SSc) Refractory to Standard Therapy |
| NCT ID | NCT07854483 |
| Phase | Phase 1 |
| Status | not yet recruiting |
| Conditions | Systemic Sclerosis (SSc); Systemic Sclerosis; Systemic Sclerosis (Scleroderma); Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria; Systemic Sclerosis Pulmonary; Systemic Sclerosis With Lung Involvement |
| Intervention types | biological |
| Target enrollment | 12 |
| Site countries | United States |
| Posted | 2026-10-02 |
| Planned start | 2027-03 |
| Event | Newly registered study |
| Event date | 2026-10-02 |

## Why this score
- Industry sponsor (buys outsourced services).
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07854483). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.